Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment.
1. How are personalised strategies impacting the treatment of melanoma? (0:11)
2. What molecular markers have been validated to inform selection of therapy? (1:04)
3. What is the main focus of current research investigating combinations of therapy in melanoma? (2:16)
4. What have been the latest advances in systemic adjuvant treatment of stage II/III melanoma? (4:20)
5. What do you see as the most important advance in melanoma treatment in recent years? (5:35)
Speaker disclosures: Paolo Ascierto has provided an advisory role for BMS, Roche, MSD, Array, Novartis, Amgen, EMD Serono, Pierre-Fabre, Incyte, Genmad, New Link Genetics, Medimmune, AstraZeneca and Sindax. He has also received research funds from BMS, Roche and Array.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
